C44.1 Categoría · se requiere mayor especificidad Other and unspecified malignant neoplasm of skin of eyelid, including canthus
ICD-10-CM C44.1 identifies “Other and unspecified malignant neoplasm of skin of eyelid, including canthus” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Excludes 11
connective tissue of eyelid (C49.0)
Instrucciones de niveles superiores
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C44 · Other and unspecified malignant neoplasm of skin
Includes2
- malignant neoplasm of sebaceous glands
- malignant neoplasm of sweat glands
Códigos más específicos
C44.10Unspecified malignant neoplasm of skin of eyelid, including canthusCategoría · se requiere mayor especificidadC44.11Basal cell carcinoma of skin of eyelid, including canthusCategoría · se requiere mayor especificidadC44.12Squamous cell carcinoma of skin of eyelid, including canthusCategoría · se requiere mayor especificidadC44.13Sebaceous cell carcinoma of skin of eyelid, including canthusCategoría · se requiere mayor especificidadC44.19Other specified malignant neoplasm of skin of eyelid, including canthusCategoría · se requiere mayor especificidadReferencias del índice oficial
Referencias desde otros códigos (1)
Excludes 1 · malignant neoplasm of eyelid (skin) (C43.1-, C44.1-)
Historial
Historial del código
Sin cambios desde la primera aparición
ModificadoSin cambios
FY2016
Vigente desde
- Primera aparición
Other and unspecified malignant neoplasm of skin of eyelid, including canthus
Categoría — seleccione un código más específico
CDC/NCHS · FY2016Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Sin cambios tabulares |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.